Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
PRPH's Cash to Debt is ranked higher than
95% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.20 vs. PRPH: No Debt )
PRPH' s 10-Year Cash to Debt Range
Min: 4.97   Max: No Debt
Current: No Debt

Equity to Asset 0.69
PRPH's Equity to Asset is ranked higher than
77% of the 754 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.59 vs. PRPH: 0.69 )
PRPH' s 10-Year Equity to Asset Range
Min: 0.48   Max: 0.96
Current: 0.69

0.48
0.96
Interest Coverage 32.00
PRPH's Interest Coverage is ranked higher than
62% of the 488 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 101.25 vs. PRPH: 32.00 )
PRPH' s 10-Year Interest Coverage Range
Min: 5.69   Max: 9999.99
Current: 32

5.69
9999.99
F-Score: 4
Z-Score: 3.38
M-Score: -1.75
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -8.89
PRPH's Operating margin (%) is ranked higher than
54% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 10.92 vs. PRPH: -8.89 )
PRPH' s 10-Year Operating margin (%) Range
Min: -87.5   Max: 49.86
Current: -8.89

-87.5
49.86
Net-margin (%) -8.96
PRPH's Net-margin (%) is ranked higher than
55% of the 786 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.26 vs. PRPH: -8.96 )
PRPH' s 10-Year Net-margin (%) Range
Min: -87.5   Max: 29.91
Current: -8.96

-87.5
29.91
ROE (%) -17.30
PRPH's ROE (%) is ranked higher than
54% of the 795 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.33 vs. PRPH: -17.30 )
PRPH' s 10-Year ROE (%) Range
Min: -32.58   Max: 97.9
Current: -17.3

-32.58
97.9
ROA (%) -12.23
PRPH's ROA (%) is ranked higher than
54% of the 814 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.07 vs. PRPH: -12.23 )
PRPH' s 10-Year ROA (%) Range
Min: -25.98   Max: 82.03
Current: -12.23

-25.98
82.03
ROC (Joel Greenblatt) (%) -41.96
PRPH's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 810 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.20 vs. PRPH: -41.96 )
PRPH' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -145.68   Max: 443.04
Current: -41.96

-145.68
443.04
Revenue Growth (%) 14.70
PRPH's Revenue Growth (%) is ranked higher than
81% of the 655 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.10 vs. PRPH: 14.70 )
PRPH' s 10-Year Revenue Growth (%) Range
Min: -32.5   Max: 125.9
Current: 14.7

-32.5
125.9
» PRPH's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2013

PRPH Guru Trades in Q3 2013

Jim Simons 66,800 sh (unchged)
» More
Q4 2013

PRPH Guru Trades in Q4 2013

Jim Simons 62,500 sh (-6.44%)
» More
Q1 2014

PRPH Guru Trades in Q1 2014

Jim Simons 47,176 sh (-24.52%)
» More
Q2 2014

PRPH Guru Trades in Q2 2014

Jim Simons 35,600 sh (-24.54%)
» More
» Details

Insider Trades

Latest Guru Trades with PRPH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Insider Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.60
PRPH's P/B is ranked higher than
85% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.39 vs. PRPH: 1.60 )
PRPH' s 10-Year P/B Range
Min: 0.87   Max: 7.44
Current: 1.6

0.87
7.44
P/S 0.90
PRPH's P/S is ranked higher than
91% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.81 vs. PRPH: 0.90 )
PRPH' s 10-Year P/S Range
Min: 0.61   Max: 4.46
Current: 0.9

0.61
4.46
EV-to-EBIT -9.87
PRPH's EV-to-EBIT is ranked higher than
56% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 30.17 vs. PRPH: -9.87 )
PRPH' s 10-Year EV-to-EBIT Range
Min: 31.8   Max: 915.6
Current: -9.87

31.8
915.6
Current Ratio 2.30
PRPH's Current Ratio is ranked higher than
71% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.28 vs. PRPH: 2.30 )
PRPH' s 10-Year Current Ratio Range
Min: 1.43   Max: 24.11
Current: 2.3

1.43
24.11
Quick Ratio 1.75
PRPH's Quick Ratio is ranked higher than
72% of the 809 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.74 vs. PRPH: 1.75 )
PRPH' s 10-Year Quick Ratio Range
Min: 0.94   Max: 19.63
Current: 1.75

0.94
19.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 20.28
PRPH's Price/Net Cash is ranked higher than
89% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PRPH: 20.28 )
PRPH' s 10-Year Price/Net Cash Range
Min: 1.4   Max: 380
Current: 20.28

1.4
380
Price/Net Current Asset Value 5.26
PRPH's Price/Net Current Asset Value is ranked higher than
93% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9999.00 vs. PRPH: 5.26 )
PRPH' s 10-Year Price/Net Current Asset Value Range
Min: 0.68   Max: 47.5
Current: 5.26

0.68
47.5
Price/Tangible Book 2.37
PRPH's Price/Tangible Book is ranked higher than
84% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.00 vs. PRPH: 2.37 )
PRPH' s 10-Year Price/Tangible Book Range
Min: 0.43   Max: 11.25
Current: 2.37

0.43
11.25
Price/Median PS Value 0.49
PRPH's Price/Median PS Value is ranked higher than
97% of the 836 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.27 vs. PRPH: 0.49 )
PRPH' s 10-Year Price/Median PS Value Range
Min: 0.23   Max: 3.6
Current: 0.49

0.23
3.6
Earnings Yield (Greenblatt) 2.30
PRPH's Earnings Yield (Greenblatt) is ranked higher than
59% of the 665 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.90 vs. PRPH: 2.30 )
PRPH' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.1
Current: 2.3

0.1
3.1
Forward Rate of Return (Yacktman) -10.80
PRPH's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 669 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.05 vs. PRPH: -10.80 )
PRPH' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -14.3   Max: 0.8
Current: -10.8

-14.3
0.8

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:GSK, JNJ, PFE, RHHBY, NVS » details
ProPhase Labs, Inc. is organized in Nevada in July 1989. The Company manufactures, markets and distributes homeopathic and health products that are offered to the general public. It also engaged in the research and development of potential over-the-counter drug, natural base health products along with supplements, personal care and cosmeceutical products. The Company also manufactures, distributues and markets over-the-counter cold remedy products to consumers through food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers. Its brand is Cold-EEZEÒ Cold Remedy and its product is Cold-EEZEÒ zinc gluconate lozenges, proven in clinical studies to reduce the duration and severity of symptoms of the common cold by nearly half. Cold-EEZEÒ is an established product in the health care and cold remedy market. Cold-EEZEÒ is its key OTC cold remedy products whose benefits are derived from its proprietary zinc gluconate formulation. The product's effectiveness has been substantiated in two double-blind clinical studies proving that Cold-EEZEÒ lozenges reduce the duration and severity of symptoms of the common cold by nearly half. The company acquired worldwide manufacturing and distribution rights to itslozenge formulation in 1992 and commenced national marketing in 1996. In August 2011, the company introduced Cold-EEZE Oral Spray containing its proprietary zinc gluconate formulation in a liquid spray form. And in August 2012 company introduced its, Cold-EEZE Cold Remedy Daytime/Nighttime QuickMelts. The Kids-EEZE products are for children suffering upper respiratory infections, allergy and/or chest congestion. Kids-EEZE products are based upon specific OTC monographs and provide single source, symptom relief through a uniquely formulated soft chew that is good-tasting, provides an accurate dose and is convenient-to-use. Its products are distributed through numerous food, multi-outlet pharmacy and chain drug stores, large wholesalers and mass merchandisers throughout the United States. The company is subject to federal and state laws and regulations adopted for the health and safety of users of pharmaceutical and health care products.
» More Articles for PRPH

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
PROPHASE LABS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 19 2014
PROPHASE LABS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Material... Sep 10 2014
ProPhase Expects to Report a $3.6 Million Impairment Charge Relating to Its Phusion Joint Venture Sep 10 2014
ProPhase Finalizes Resolution of Long-Standing Litigations Sep 10 2014
PROPHASE LABS, INC. Financials Aug 19 2014
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Aug 18 2014
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report Aug 12 2014
ProPhase Labs Reports Financial Results for the Three and Six Months Ended June 30, 2014 Aug 12 2014
PROPHASE LABS, INC. Files SEC form 8-K, Other Events Jun 27 2014
PROPHASE LABS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... Jun 19 2014
PROPHASE LABS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial... May 29 2014
ProPhase Labs establishes 3M share equity line May 29 2014
ProPhase Establishes 3.0 Million Share Equity Line May 29 2014
CEO of ProPhase Labs Ups Ad Spend in Response to ESPN On-Air Commentator May 28 2014
PROPHASE LABS, INC. Files SEC form 8-K, Other Events May 23 2014
PROPHASE LABS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders May 22 2014
PROPHASE LABS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 13 2014
PROPHASE LABS, INC. Files SEC form 10-Q, Quarterly Report May 12 2014
ProPhase Labs Reports Financial Results for the First Quarter Ended March 31, 2014 May 12 2014
4 Stocks Under $10 Moving Higher Mar 28 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK